Skip to main content

Table 4 IL28B and IL10R −1087 genotype combinations in the different study groups

From: IL28B and IL10R −1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort

 

IL28B genotype

 

CC

CC

T allele

T allele

IL10R genotype

HCV n = 664

GG

61 (9.2%)

OR:0.322 (0.186-0.556)

148 (22.3%)

0.728 (0.446-1.188)

A allele

107 (16.1%)

p < 0.001

348 (52.4%)

p = 0.202

Controls n = 92

GG

22 (23.9%)

OR:0.515 (0.311-0.852)

26 (28.3%)

OR:4.231 (2.497-7.169)

A allele

25 (27.2%)

p = 0.009

19 (20.7%)

p < 0.001

SVR n = 178

GG

22 (12.4%)

OR:1.648 (0.837-3.247)

37 (20.8%)

OR:0.803 (0.496-1.301)

A allele

38 (21.3%)

p = 0.146

81 (45.6%)

p = 0.372

Non-responders n = 203

GG

16 (7.9%)

OR: 1.848 (1.070-3.190)

50 (24.6%)

OR:0.692 (0.462-1.037)

  

A allele

26 (12.8%)

p = 0.026

(54.7%)111

p = 0.074

  1. Prevalence of IL28B CC plus IL10R GG in HCV patients vs. controls OR: 0.322.
  2. IL28B CC plus IL10R A allele OR: 0.515.
  3. IL28B T allele plus IL10R A allele OR: 4.231.
  4. Prevalence of IL28B CC plus IL10R A allele in pts with SVR vs. non-responders OR:1.848.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us